TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
NCT06802081 on ClinicalTrials.gov · last registry update 2026-01-13
Recruiting now, toward 100 participants. Due to report 31 December 2026, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: AFib burden. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is approved in the US, but not for atrial fibrillation — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- RECRUITING
- Phase
- P2
- Drug
- tirzepatideZepbound, Mounjaro
- Sponsor
- The Cleveland Clinic
- Sponsor type
- Other
- Enrollment
- 100
- Started
- 2025-04-08
- Primary completion
- 2026-12-31 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
AFib burden
Conditions studied
Atrial Fibrillation · Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.